《大行》高盛料阿里健康(00241.HK)2026财年业绩指引仍存上行空间 升目标价至5.2元

阿斯达克财经
Dec 02, 2025

高盛研报指,阿里健康(00241.HK) 公布9月底止2026财年中期业绩后,维持其“中性”评级,主要原因包括公司正受惠于产业结构性的利好因素,如原研处方药从医院渠道流出及线上药品渗透率的加速增长。然而,高盛观察到两大线上医药平台阿里健康及京东健康(06618.HK) 在收入增长上存在差异,当中包括第一方平台销售(1P)已成为主要收入和利润驱动因素下,相较于同行,阿里健康在建立完善的第一方平台销售...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10